| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Sophia Lionaki | Q59193494 |
| P2093 | author name string | John N Boletis | |
| Aliki Iniotaki | |||
| Konstantinos Panagiotellis | |||
| P2860 | cites work | Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA | Q22010440 |
| Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells | Q24316370 | ||
| A second lineage of mammalian major histocompatibility complex class I genes | Q24561936 | ||
| Detection and clinical relevance of donor specific HLA antibodies: a matter of debate | Q26998713 | ||
| Compartmental localization and clinical relevance of MICA antibodies after renal transplantation | Q33648605 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Humoral theory of transplantation | Q35142603 | ||
| Human leukocyte antigen antibodies for monitoring transplant patients | Q36202286 | ||
| De Novo Donor-Specific HLA Antibody Development and Peripheral CD4(+)CD25(high) Cells in Kidney Transplant Recipients: A Place for Interaction? | Q36204503 | ||
| Humoral theory of transplantation: further evidence | Q36228533 | ||
| Sensitization after kidney transplantation | Q36910397 | ||
| Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival | Q37315152 | ||
| The role of major histocompatibility complex class I chain-related gene A antibodies in organ transplantation | Q37554232 | ||
| Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe? | Q38001495 | ||
| The impact of donor-specific anti-HLA antibodies on late kidney allograft failure | Q38003049 | ||
| Incidence and impact of de novo donor-specific alloantibody in primary renal allografts | Q39472834 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients | Q39951249 | ||
| Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure | Q40386334 | ||
| Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes | Q42553965 | ||
| Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection | Q43041922 | ||
| Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies | Q43178469 | ||
| HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss | Q43288501 | ||
| Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques | Q43618124 | ||
| Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 | ||
| Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. | Q43931517 | ||
| Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report | Q43937861 | ||
| Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. | Q44092564 | ||
| Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation | Q44215754 | ||
| Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation | Q44699496 | ||
| Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification | Q44919347 | ||
| Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts | Q45287212 | ||
| Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction | Q45309367 | ||
| Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. | Q45972310 | ||
| De novo donor specific antibodies and patient outcomes in renal transplantation | Q46293237 | ||
| Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. | Q46683381 | ||
| Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. | Q47206753 | ||
| Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules | Q47272995 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
| Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 | ||
| Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. | Q50765005 | ||
| Cytotoxic antibodies monitoring in kidney transplantation--their clinical relevance and challenges. | Q50910425 | ||
| Structural aspects of human leukocyte antigen class I epitopes detected by human monoclonal antibodies. | Q51455008 | ||
| Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays--single-center experience. | Q51930565 | ||
| Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. | Q52668051 | ||
| Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. | Q53243295 | ||
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 | ||
| Intracellular Expression of MICA in Activated CD4 T Lymphocytes and Protection from NK Cell-Mediated MICA-Dependent Cytotoxicity | Q61625329 | ||
| Successful transplantation with a positive T and B cell crossmatch due to autoreactive antibodies | Q72786532 | ||
| Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients | Q73128653 | ||
| Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome1 | Q73276645 | ||
| The clinical importance of alloantibody-mediated rejection | Q73465298 | ||
| Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts | Q74550738 | ||
| Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes | Q77859935 | ||
| All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies | Q78534560 | ||
| Pathology and the allo-immune response | Q79312276 | ||
| Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study | Q80054538 | ||
| Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine | Q80068380 | ||
| Detection of HLA and MICA antibodies before kidney graft failure | Q80952177 | ||
| Antibodies against MICA antigens and kidney-transplant rejection | Q81357717 | ||
| Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels | Q81964906 | ||
| Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation | Q82516684 | ||
| Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay | Q83063969 | ||
| Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients | Q84258967 | ||
| De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy | Q84464302 | ||
| Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts | Q84512213 | ||
| Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 | ||
| De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure | Q84752864 | ||
| The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy | Q84758677 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | antibody | Q79460 |
| globulins | Q321710 | ||
| blood proteins | Q425056 | ||
| kidney transplantation | Q740909 | ||
| P304 | page(s) | 849835 | |
| P577 | publication date | 2013-11-21 | |
| P1433 | published in | Clinical and Developmental Immunology | Q15754140 |
| P1476 | title | Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation | |
| P478 | volume | 2013 |
| Q38966041 | Advances in diagnostics for transplant rejection |
| Q64915491 | Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity. |
| Q48955987 | De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis |
| Q38429887 | Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival |
| Q64059804 | Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study |
| Q39217968 | Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection |
| Q47100818 | Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant |
| Q40636545 | Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients |
| Q64118786 | Psychosocial Assessment of Candidates for Transplantation (PACT) Score Identifies High Risk Patients in Pediatric Renal Transplantation |
| Q92381767 | Role of de novo DQ donor-specific antibody in antibody-mediated rejection in renal transplant recipient: A case study |
| Q36662281 | Some considerations on the current debate about typing resolution in solid organ transplantation |
| Q39121357 | The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives. |
| Q35175413 | Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. |
Search more.